AMBIENCE
a Phase 3, randomised, double blind, placebo controlled trial to confirm superiority of amycretin versus placebo added to standard of care on time to 4-P MACE in patients with established CVD and obesity or overweight.
- Stage
- inclusie
- Medicine
- Amycretin
- Population
- ASCVD
- Phase
- IIIb
- First Patient In
- 26 October 2026
- Last Patient In
- 22 October 2028
- Last Patient Last Visit
- 15 August 2030
Inclusion period, 731 days remaining
National Lead
prof. dr. F.M.A.C. Martens
Cardioloog
Study Director
dr. C. van Ofwegen-Hanekamp
Cardioloog
Office Contact
